A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Exploratory Study to Investigate NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Skin disorders
- Focus Therapeutic Use
- Acronyms LESS
- Sponsors Merz North America
- 23 Aug 2024 Status changed from active, no longer recruiting to completed.
- 05 Jun 2024 Planned End Date changed from 1 Dec 2024 to 1 Aug 2024.
- 05 Jun 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2024.